

## AMENDMENT

### Listing of the Claims

The following listing of claims replaces all previous listings or version thereof:

1. (Currently amended) A method of treatinginhibiting pathologic cardiac hypertrophy or heart failureand hypertension in a human patient comprising:
  - (a) identifying a human patient having cardiac hypertrophy or heart failureand hypertension;
  - (b) administering to said patient an inhibitor of Protein Kinase D (PKD); and
  - (c) administering to said patient a beta blocker,

wherein said PKD inhibitor reduces hypertrophic signaling and inhibits hypertrophy in cardiac tissue of said human patient, and said beta blocker reduces hypertension in said human patient.
2. (Original) The method of claim 1, wherein said inhibitor of PKD is selected from the group consisting of resveratrol, indolocarbazoles, Godecke 6976 (Go6976), staurosporine, K252a, Substance P (SP) analogues including [d-Arg(1),d-Trp(5,7,9), Leu(11)]SP, PKC inhibitor 109203X (GF-1), PKC inhibitor Ro 31-8220, GO 7874, Genistein, the specific Src inhibitors PP-1 and PP-2, chelerythrine, rottlerin, a PKD RNAi molecule, a PKD antisense molecule, a PKD ribozyme molecule or a PKD-binding single-chain antibody, or expression construct that encodes a PKD-binding single-chain antibody.
3. (Original) The method of claim 1, wherein administering the inhibitor of PKD is performed intravenously or by direct injection into cardiac tissue.

4. (Original) The method of claim 1, wherein administering comprises oral, transdermal, sustained release, controlled release, delayed release, suppository, or sublingual administration.

5-6. (Canceled)

7. (Currently amended) The method of claim 1, wherein said ~~second therapybeta blocker~~ is administered at the same time as said inhibitor of PKD.

8. (Currently amended) The method of claim 1, wherein said ~~second therapybeta blocker~~ is administered either before or after said inhibitor of PKD.

9-100. (Canceled)